Measuring healthy female nulliparous pubovisceral muscle from diffusion kurtosis imaging

This study explores the feasibility of using diffusion kurtosis imaging (DKI) in the pelvic floor region and assesses the water diffusivity of the pubovisceral muscle. Twenty-seven healthy young nulliparous females underwent DKI at 3.0 T that included 15 gradient directions and three b values (0, 750, and 1500 s/mm²). The diffusion tensor and diffusion kurtosis metrics values of the pubovisceral muscle were measured after image processing. Two independent sample t-tests, a paired-samples t-test, and a nonparametric hypothesis test were performed as appropriate to compare the differences among different metrics. Twenty-six subjects (mean ± standard deviation age, 25 ± 2 years) were successfully analyzed by measuring the diffusion tensor and diffusion kurtosis metrics of the bilateral pubovisceral muscles. The metrics included mean kurtosis, axial kurtosis, radial kurtosis, fractional anisotropy, mean diffusivity, axial diffusivity, and radial diffusivity. We found no statistically significant differences for these measurement values between the left and right pubovisceral muscles (p = 0.271–0.931). However, radial kurtosis was greater than axial kurtosis in both pubovisceral muscles (p < 0.001) and axial diffusivity was lower than radial diffusivity in both pubovisceral muscles (p < 0.001). We deem the application of DKI technology to the pelvic floor region to be feasible.     

UV法测定奥美沙坦酯氨氯地平片含量均匀度

目的 建立测定奥美沙坦酯氨氯地平片含量均匀度的方法.方法 采用UV法,奥美沙坦酯的测定波长采用285 nm,苯磺酸氨氯地平测定波长采用360 nm.奥美沙坦酯的检测质量浓度为80μg/mL,氨氯地平的检测质量浓度为20μg/mL.以对照品比较法计算奥美沙坦酯氨氯地平片中奥美沙坦酯和氨氯地平的含量均匀度.结果 奥美沙坦酯和氨氯地平对照品溶液质量浓度分别在48.23～128.61μg/mL和12.17～32.46μg/mL范围内与吸光度呈良好线性关系;奥美沙坦酯与氨氯地平的平均回收率分别为99.26％、100.13％,RSD分别为0.33％、0.49％;样品溶液8 h内稳定;测定的3批奥美沙坦酯氨氯地平片中奥美沙坦酯与氨氯地平含量均匀度均在合格范围内,A+2.2S≤15.0.结论 采用UV法测定奥美沙坦酯氨氯地平片中奥美沙坦酯和氨氯地平的含量均匀度准确、快速、经济.     

莱姆病的临床特点及处置要点

莱姆病是由伯氏疏螺旋体（Borrelia burgdorferi）引起的自然疫源性疾病，发病地区不断扩展蔓延，发病率逐年上升，其中，森苏疏螺旋体（B.burgdorferi sensu）、阿氏疏螺旋体（Borrelia afzelii）和加里尼疏螺旋体（Borrelia garinii）等三种基因分型的伯氏疏螺旋体与莱姆病发病密切相关。莱姆病螺旋体基因型的分布与地理环境、媒介生物、宿主动物密切相关，不同基因型引起的临床表现差异巨大。莱姆病临床表现可分为三个阶段：早期局灶期表现为蜱虫叮咬部位的游走性红斑，播散期可出现多发性红斑、螺旋体淋巴细胞瘤、神经系统莱姆病、心肌炎或关节炎，晚期发散期表现为慢性萎缩性关节炎和神经系统损伤症状。     

孤独症谱系障碍社会脑神经网络基础及其研究进展

孤独症谱系障碍(ASD)的核心诊断特征是社会交流障碍以及受限和重复的行为和兴趣,症状常在生命的最初几年出现。过去的二十年内,神经成像揭示了许多“社会性”大脑的非典型活动和异常连通性的发现,包括梭状回对面部和凝视的分析、杏仁核的情绪处理、默认模式网络的心智化以及镜像神经元相关区域对他人行为的模仿和理解,但对于社交功能缺陷潜在的神经生理机制还未达成一致。除了方法学上的挑战以及聚焦于单个大脑网络的连通性研究以外,更深层次的问题是ASD的极强异质性。这种不一致的发现,可能是由于诊断标准的变化以及学龄前期的ASD患儿存在非典型的神经发育轨迹,因此,有必要进行孤独症亚型的队列研究和大样本的纵向队列研究。     

基于中国传统运动疗法的慢性筋骨病康复模式构建思路探析＊

中国传统运动疗法作为极具特色的康养健身运动疗法，在防病治病中的宝贵价值备受国际康复医学界关注。而慢性筋骨病是骨伤科临床中的常见病、多发病与疑难杂病，临床呈现出“一大五多五高”的特征，成为当前重大的健康问题与临床防治研究课题。本文通过深入探究中国传统运动疗法特点以及其在慢性筋骨病康复中的应用原理、原则及优势作用，提出以传统运动疗法为依托，构建慢性筋骨病防病治病应用方法模式；以三因制宜为指导，构建医院-社区-团体-患者为一体的康复管理模式；以“治未病”工程为支撑，构建慢性筋骨病管理信息资源共享平台模式；为切实提高防、控、治的能力与水平找准抓手与路径，为构建慢性筋骨病康复模式提供新的思路与方向。     

Proxalutamide in metastatic castration-resistant prostate cancer: Primary analysis of a multicenter,randomized, open-label,phase 2 trial

We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177).